Which tyrosine kinase inhibitor is most effective for CML treatment?
There isn't one "most effective" TKI for everyone with CML. The FDA has approved several TKIs that work well as first-line treatments for newly diagnosed CML:
* Imatinib (Gleevec)
* Dasatinib (Sprycel)
* Bosutinib (Bosulif)
* Nilotinib (Tasigna)
* Show Full Answer
Which tyrosine kinase inhibitor is most effective for CML treatment?
There isn't one "most effective" TKI for everyone with CML. The FDA has approved several TKIs that work well as first-line treatments for newly diagnosed CML:
* Imatinib (Gleevec)
* Dasatinib (Sprycel)
* Bosutinib (Bosulif)
* Nilotinib (Tasigna)
* Asciminib (Scemblix)
Almost all people with CML respond well to imatinib, and many do so for years. It was the first TKI approved and has been studied for up to 14 years with proven effectiveness.
However, the best choice depends on your specific situation, including any genetic mutations in your cancer cells, how you respond to treatment, and potential side effects. Some people develop resistance to certain TKIs over time and may need to switch to a different one.
If you have the T315I mutation or if other TKIs haven't worked, ponatinib (Iclusig) or asciminib may be options.
Your oncology team can help determine which TKI is right for your specific case of CML.
February 2
Join
Your Privacy Choices
